The information contained in these regimens is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. The treatment regimen to be used should take into account factors such as histology, molecular pathology, age, performance status, co-morbidities and the patient’s preference. Each treatment regimen has advantages and disadvantages, and there may be more than one good option. In addition, treatment choices can change over time as more evidence becomes available. Use of these documents is the responsibility of the prescribing clinician and is subject to the HSE.ie terms of use.
Please email any comments or feedback on these regimens to oncologydrugs@cancercontrol.ie
Allogeneic Transplant
| Regimen Name |
Indication |
|
Busulfan/Cyclophosphamide–MAC–MUD
Regimen
|
00639a
Myeloablative conditioning for matched unrelated donor allogeneic stem cell transplant in patients with myeloid disorders.
|
|
Busulfan/Cyclophosphamide – MAC – SIB
Regimen
|
00641a
Myeloablative conditioning for sibling donor allogeneic stem cell transplant in patients with myeloid disorders.
|
|
Busulfan/Cyclophosphamide/ATG Grafalon® – MAC – Mismatched Sibling Donor
Regimen
|
00662a
Myeloablative conditioning for mismatched sibling donor allogeneic stem cell transplant in patients with myeloid disorders.
|
|
Busulfan/Cyclophosphamide/ATG Grafalon® – MAC – Mismatched Unrelated Donor
Regimen
|
00663a
Myeloablative conditioning for mismatched unrelated donor allogeneic stem cell transplant in patients with myeloid disorders.
|
|
Carmustine/Etoposide/Cytarabine/Melphalan/Alemtuzumab RIC-SIB/MUD
Regimen
|
00638a
Reduced intensity conditioning for sibling or matched unrelated allogeneic stem cell transplantation in Hodgkins and Non-Hodgkins Lymphoma.
|
|
Cyclophosphamide/Total Body Irradiation (TBI)–MAC–MUD
Regimen
|
00631a
Myeloablative conditioning (MAC) for matched unrelated donor allogeneic stem cell transplant in patients with lymphoid disorders and acute or chronic leukaemias.
|
|
Cyclophosphamide/Total Body Irradiation (TBI)–MAC–SIB
Regimen
|
00637a
Myeloablative conditioning (MAC) for sibling donor allogeneic stem cell transplant in patients with lymphoid disorders.
|
|
Cyclophosphamide/Total Body Irradiation (TBI)–MAC–Mismatched Sibling Donor
Regimen
|
00630a
Myeloablative conditioning (MAC) for mismatched sibling donor allogeneic stem cell transplant in patients with lymphoid disorders.
|
|
Cyclophosphamide/Total Body Irradiation (TBI)–MAC–Mismatched Unrelated Donor
Regimen
|
00629a
Myeloablative conditioning (MAC) for mismatched unrelated donor allogeneic stem cell transplant in patients with lymphoid disorders and acute or chronic leukaemias.
|
|
Fludarabine/Busulfan/ATG Grafalon® – RIC – MUD
Regimen
|
00635a
Reduced intensity conditioning for matched unrelated donor allogeneic stem cell transplant in patients with myeloid disorders.
|
|
Fludarabine/Busulfan/ATG Grafalon® – RIC –SIB
Regimen
|
00636a
Reduced intensity conditioning for sibling donor allogeneic stem cell transplant in patients with myeloid disorders.
|
|
Fludarabine/Melphalan/Alemtuzumab-RIC-MUD
Regimen
|
00625a
Reduced intensity conditioning for matched unrelated donor allogeneic stem cell transplant in patients with lymphoproliferative disorders.
|
|
Fludarabine/Melphalan/Alemtuzumab-RIC-SIB
Regimen
|
00611a
Reduced intensity conditioning for sibling donor allogeneic stem cell transplant in patients with lymphoproliferative disorders.
|
Autologous Transplant
| Regimen Name |
Indication |
|
BEAM Autologous Transplant Conditioning Protocol
Regimen
|
00408a
Autologous conditioning in non-Hodgkins Lymphoma (NHL).
00408b
Autologous conditioning in Hodgkins Lymphoma.
|
|
LEAM Autologous Transplant Conditioning Protocol
Regimen
|
00468a
Autologous conditioning in non-Hodgkins Lymphoma (NHL).
00468b
Autologous conditioning in Hodgkins Lymphoma.
|
|
High Dose Melphalan Conditioning Therapy for Autologous Stem Cell Transplant
Regimen
|
00454a
Conditioning Therapy in patients with Multiple Myeloma prior to autologous stem cell transplant.
00454b
Conditioning Therapy in patients with other plasma cell dyscrasia such as AL amyloidosis.
|
